Q1 EPS Forecast for Alto Neuroscience Reduced by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities research analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for shares of Alto Neuroscience in a report released on Wednesday, March 18th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.63) per share for the quarter, down from their previous forecast of ($0.59). The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q2 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at ($3.44) EPS, FY2028 earnings at ($4.11) EPS, FY2029 earnings at ($2.99) EPS and FY2030 earnings at ($1.16) EPS.

A number of other brokerages have also recently weighed in on ANRO. Jefferies Financial Group restated a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a research report on Monday. Wedbush increased their price objective on shares of Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. BTIG Research lifted their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.33.

Alto Neuroscience Stock Down 3.0%

ANRO opened at $21.38 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.42 and a current ratio of 15.69. The company has a market cap of $683.04 million, a price-to-earnings ratio of -9.81 and a beta of 2.52. Alto Neuroscience has a one year low of $1.60 and a one year high of $25.17. The business’s fifty day moving average is $18.47 and its two-hundred day moving average is $13.60.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11.

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AlphaCore Capital LLC raised its position in shares of Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after buying an additional 10,000 shares during the last quarter. Bank of Montreal Can acquired a new stake in Alto Neuroscience during the second quarter worth approximately $25,000. 683 Capital Management LLC acquired a new stake in Alto Neuroscience during the fourth quarter worth approximately $1,153,000. Spruce Street Capital LP purchased a new stake in Alto Neuroscience in the 4th quarter worth approximately $3,967,000. Finally, AdvisorShares Investments LLC purchased a new stake in Alto Neuroscience in the 4th quarter worth approximately $785,000.

Alto Neuroscience News Summary

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Robert W. Baird raised its price target to $41, which can support upside sentiment and buying interest for growth/biotech investors. Robert W. Baird Boosts Alto Neuroscience (NYSE:ANRO) Price Target to $41.00
• Positive Sentiment: Wedbush reiterated a constructive outlook for Alto and flagged potential strong price appreciation, supporting demand from momentum/coverage-driven buyers. Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock
• Positive Sentiment: Chardan Capital reaffirmed its Buy rating, another supportive analyst signal for investor confidence. Chardan Capital Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)
• Neutral Sentiment: Recent quarterly report (Mar 16) slightly beat EPS consensus, which provides some fundamental support versus the negative estimate revisions. Alto Neuroscience — Company Page
• Negative Sentiment: HC Wainwright issued a broad set of downward revisions (Mar 18) to Alto’s near- and medium-term EPS: Q1 2026 to ($0.63) from ($0.59), Q2 2026 to ($0.67) from ($0.64), Q4 2026 to ($0.74) (earlier view higher), FY2026 to ($2.75) from ($2.51), and sharper cuts to FY2027–FY2029/FY2028 (e.g., FY2028 to ($4.11) from ($2.65); FY2029 to ($2.99) from ($1.54)). These more bearish earnings trajectories increase uncertainty on cash burn and timing to profitability, which likely explains much of the downward pressure on the stock today. HC Wainwright Lowers Earnings Estimates for Alto Neuroscience

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.